Delivery of Intraocular Triamcinolone Acetonide in the Treatment of Macular Edema

If you need an accessible version of this item, please submit a remediation request.
Date
2012-03-15
Language
American English
Embargo Lift Date
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
MDPI
Abstract

Macular edema (ME) is one of the eventual outcomes of various intraocular and systemic pathologies. The pathogenesis for ME is not yet entirely understood; however, some of the common risk factors for its development have been identified. While this investigation will not discuss the numerous etiologies of ME in detail, it appraises the two most widely studied delivery modalities of intraocular corticosteroids in the treatment of ME—intravitreal injection (IVI) and sub-Tenon’s infusion (STI). A thorough review of the medical literature was conducted to identify the efficacy and safety of IVI and STI, specifically for the administration of triamcinolone acetonide (TA), in the setting of ME in an attempt to elucidate a preferred steroid delivery modality for treatment of ME.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Pickrell, A., Harris, A., Ngo, S., Amireskandari, A., Stewart, E., & Siesky, B. (2012). Delivery of Intraocular Triamcinolone Acetonide in the Treatment of Macular Edema. Pharmaceutics, 4(1), 230–242. https://doi.org/10.3390/pharmaceutics4010230
ISSN
1999-4923
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Pharmaceutics
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
Final published version
Full Text Available at
This item is under embargo {{howLong}}